Regeneron Pharmaceuticals Inc.REGN

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · regeneron.com

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic diseases, cancer, infectious diseases, and rare disorders. Key products include EYLEA for macular degeneration, Dupixent for atopic dermatitis and asthma, and Libtayo for certain skin cancers. The company is headquartered in Tarrytown, New York.

Key ratios

Operating cash flow growth

-1.3%TTM

2025 12.6%2024 -3.8%2023 -8.4%

EPS growth

1.9%TTM

2025 8.2%2024 10.3%2023 -9.0%

FCF / Sales

24.2%TTM

2025 28.4%2024 25.8%2023 29.5%

Net margin

27.9%TTM

2025 31.4%2024 31.1%2023 30.1%

ROA

6.5%TTM

2025 5.9%2024 7.3%2023 8.5%

ROE

14.0%TTM

2025 14.9%2024 16.0%2023 16.3%

Revenue growth

9.3%TTM

2025 1.0%2024 8.3%2023 7.8%

Recent news

Regeneron Announces Investor Conference Presentations 2026-08-19 · GlobeNewswire Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP) 2026-08-19 · GlobeNewswire Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation 2026-07-31 · GlobeNewswire Regeneron Reports Second Quarter 2026 Financial and Operating Results 2026-07-30 · GlobeNewswire Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast 2026-06-25 · GlobeNewswire Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO 2026-06-04 · GlobeNewswire

Track REGN in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer